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The Fritz Bender Stiflung and the Genome Institute of 
Singapore  hosted  a  meeting  at  the  Biopolis  to  address 
fundamental questions of how molecular genetics could 
advance  cancer  therapies.  Participating  in  the  meeting 
were basic biologists and molecular geneticists who are 
tackling  the  changes  accompanying  cancer,  as  well  as 
those  immersed  in  new  drug  development,  including 
specialists in trial design to match patients to the correct 
therapy. Despite the vast sums of resources devoted to 
cancer therapy, there remain entire classes of cancers for 
which  present  therapies  offer  little  hope,  and  other 
classes that are chronically overtreated, with associated 
morbidity, because we simply cannot distinguish which 
patients need the treatments. Personalized medicine for 
cancer therapy is thus not a program of profligate drug 
development to counter the hundreds of changes known 
to occur in cancer, but rather tailoring those treatments 
we  have  to  the  right  patients  and  ensuring  that  new 
therapies developed have the greatest shot at filling the 
major gaps in therapies that exist for nearly all cases of 
pancreatic  cancer,  gastric  and  esophageal  adeno  carci­
noma, and liver cancer and glioblastoma, to name a few.
Drivers versus back-seat drivers of cancer
Edison Liu (Genome Institute of Singapore, Singapore) 
introduced Enrico Mihich (Dana Farber Cancer Institute, 
USA) as being a ray of hope because he pioneered the 
original chemotherapies that have brought real progress 
in the treatment of a host of cancers. Mihich encouraged 
the  patience  and  perseverance  that  have  led  to  the 
eradication  of  a  number  of  chemotherapy­susceptible 
cancers in a steady process of clinical trials and histo­
logical  stratifications,  and  suggested  that  the  available 
tools and drug candidates should greatly accelerate the 
process  he  formulated  so  successfully.  Liu  discussed 
cancer as an evolutionary process involving point muta­
tions,  genomic  rearrangements  and  epigenetic  changes 
that ultimately conspired to make it less obvious as to 
what were ‘driver’ mutations versus ‘passenger’ muta  tions; 
he suggested that the latter might be better described as 
‘backseat  driver’  mutations  influencing  the  drivers.  He 
focused  on  the  rapidly  accumulating  information  on 
genomic rearrangements derived from pair­end­tag (PET) 
technologies,  presenting  evidence  from  MCF­7  breast 
cancer  and  breast  cancer  tumor  genomes  for  fusion 
genes,  of  which  nearly  50%  yielded  transcribed  fusion 
proteins, and he discussed what these elements are telling 
us  about  cancers  in  general.  Yijun  Ruan  (Genome 
Institute of Singapore, Singapore) further discussed PET 
technologies for rapidly assessing sequence variation in 
the genome and its application to gastric cancers. Early 
results  indicate  that  most  inversions,  deletions  and 
insertions are germline in origin, whereas cancers display 
tandem duplications, unpaired inversions, interchromo­
somal  translocations  and  complex  rearrangements. 
Amplifications in general are in the form of large tandem 
duplications  by  mitotic  crossovers.  In  general,  he  has 
found that, from approximately 2,000 sequence variations 
introduced  into  the  cancer  genome,  only  12  of  these 
appear to be recurrent in the limited set of gastric cancers 
he has tested.
Stratifying drugs and patients
There were also several interesting talks discussing the 
challenges  in  oncology  drug  development.  These  were 
given by Richard Gaynor (Eli Lilly, USA), Eileen Dolan 
(University  of  Chicago,  USA),  Elizabeth  Eisenhauer 
(Queen’s University, Canada) and Sun Young Rha (Yonsei 
University, Korea). Gaynor highlighted that only 10% of 
drugs taken to clinical trial make it in the commercial 
market, suggesting that more information about tumor 
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selection  is  required.  Somehow  all  of  this  information 
needs marshaling to stratify patients to match with drugs 
and  drug  combinations.  Dolan  has  developed  whole­
genome approaches to identifying gene sets that affect 
sensitivity to chemotherapeutics in different ethnic popu­
lations, and has attributed these to co­regulated trans­
criptional blocks. Eisenhauer described the challenges of 
clinical  trials  in  the  face  of  so  many  new  targeted 
therapies, such as those targeting cell surface receptors 
and  intracellular  signaling  pathways,  including  how  to 
define efficacy, when to identify biomarkers, and how to 
choose which therapeutic direction to support.
From cancer cell biology to the clinic
In addition, several speakers discussed their experience 
of translating the key findings in basic biology to clinical 
strategies.  Carl  Novina  (Dana  Farber  Cancer  Institute, 
USA) and Frank Slack (Yale University, USA) presented 
animated analyses of the role of microRNAs and their 
targets in cancer, including SNPs in the oncogene KRAS 
that disrupt binding sites of microRNA Let7 in patients 
with  particular  cancers.  Sir  David  Lane  (A*STAR 
Institute of Medical Biology, Singapore) spoke on emer­
ging strategies focused on the common defects in the p53 
pathway in cancer cells, with novel strategies to target 
mutant p53 but spare wild­type p53 in order to protect 
normal  cells  from  therapy.  Stephen  Baylin  (The  Johns 
Hopkins University School of Medicine, USA) described 
a  new  understanding  of  how  cancer  cells  assume  epi­
genetic marks of stem cells, and how this knowledge is 
being  funneled  into  clinical  trials  of  drugs  targeting 
epigenetic  markers.  Quang  Yu  (Genome  Institute  of 
Singapore, Singapore) reported that epigenetic silencing 
of  a  subunit  of  PP2A,  common  in  most  colorectal 
cancers, leads to resistance to the mammalian target of 
rapamycin  (mTOR)  inhibitor  rapamycin,  and  that  this 
resis  tance can be restored by PDK1 (pyruvate dehydro  ge­
nase kinase isozyme 1) inhibition, but not phosphatidyl­
inositol 3­kinase pathway inhibition. Wa Xian (A*STAR 
Institute  of  Medical  Biology,  Singapore)  and  Frank 
McKeon  (Genome  Institute  of  Singapore,  Singapore) 
con  tri  buted  to  a  talk  describing  work  to  identify  the 
origin of Barrett’s esophagus using a mouse model, and 
how  this  finding  can  influence  the  diagnosis  and 
treatment of a lethal cancer, esophageal adenocarcinoma.
Asian-specific strategies
Finally, the influence of the Asian genome in diseases was 
reported by Yixin Zeng (Sun Yat­Sen University Cancer 
Center,  China)  and  Sin  Tiong  Ong  (Duke­National 
University of Singapore Graduate Medical School, Singa­
pore).  Zeng  discussed  susceptibility  to  nasopharangeal 
carcinoma, which is highest in the Gaungxi province of 
southern China. Genome­wide association studies have 
clearly linked this susceptibility to HLA loci as well as 
additional regions on four other chromosomes, and Zeng 
discussed  how  these  might  interact  with  Epstein­Barr 
virus  and  how  mechanistic  studies  might  lead  to  new 
therapeutics to suppress these cancers. Ong presented an 
intriguing  study  of  why  Gleevec  and  related  tyrosine 
kinase inhibitors (TKIs) are less effective in Asians with 
chronic myelogenous leukemia. He showed very recent 
data on particular structural variations in the genomes of 
patients  from  East  Asia.  These  variations  have  been 
found to be tightly linked to resistance to TKIs and are 
present in 13% to 18% of the population of East Asia, and 
they clearly implicate defects in apoptotic mechanisms 
underlying resistance. Consideration of these variations 
is precisely the goal of personalized medicine, and Ong 
suggested  possible  therapeutic  approaches  to  enhance 
TKI function in this population.
The need for better patient stratification
Kurt Zaenker summed up the meeting by reminding us 
of Enrico Mihich’s description of the early and darker 
days  of  chemotherapy  and  how  those  drugs,  as  non­
specific  as  they  are,  were  molded  over  decades  into 
highly  effective  therapies  for  a  wide  range  of  cancers. 
The next phase, he noted, would require a more in­depth 
under  standing  of  cancers  at  the  molecular  level  made 
possible  by  remarkable  advances  in  cell  and  genetic 
technologies. This information should allow us to stratify 
cancers by molecular markers, assist in the identification 
of  new  drug  targets,  and  provide  the  patient 
characteristics and biomarkers to ensure that effective 
new therapies achieve approval through the use of best­
matched trials. So, why is there so much effort to get 
more new, expensive drugs into cancer treatment that 
might  only  marginally  extend  life  (often  measured  in 
months)?  Zaenker  went  back  to  Mihich’s  earlier 
experience  with  chemotherapeutics  that  showed  that 
few cancers could be met head on with single agents. As 
more new drugs become approved, greater numbers of 
combinatorial trials and treatments will begin to address 
the  remarkable  genetic  diversity  apparent  in  the 
genomes of cells that comprise these cancers.
Abbreviations
HLA, human leukocyte antigen; PET, pair-end tagging; SNP, single-nucleotide 
polymorphism; TKI, tyrosine kinase inhibitor.
Published: 19 April 2011
doi:10.1186/gm236
Cite this article as: Xian W, McKeon F: The challenges and hopes of 
personalized cancer medicine. Genome Medicine 2011, 3:22.
Xian and McKeon Genome Medicine 2011, 3:22 
http://genomemedicine.com/content/3/4/22
Page 2 of 2